CMPD one for 25 reverse split. PPS closed at .15

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

$CMPD CompuMed Press Release re Reverse Stock SplitPress Release | 04/20/2022

LOS ANGELES, CA / ACCESSWIRE / April 20, 2022 / CompuMed, Inc. (OTC PINK:CMPD), a leader in providing diagnostic telemedicine, announced in March 2022 the approval by its stockholders of a 25:1 reverse stock split.

As previously disclosed, the Company is in the process of submitting the appropriate documents to FINRA and its transfer agent, ComputerShare, to effect the reverse stock split as quickly as possible, with an anticipated effective date in mid - May 2022; the Company will provide updates as the effective date becomes closer.

Inquiries regarding this can be sent to investorrelations@compumedinc.com

About CompuMed, Inc.

CompuMed, Inc. (OTC PINK:CMPD) Diagnostic Telemedicine services provide patients with the highest level of clinical care at reduced costs. Its telecardiology and teleradiology offerings provide real-time access to U.S. Board-Certified specialists through cloud-based technology and integrated medical devices to medical facilities anywhere in the world. The company has been in business over 26 years and services over 1,000 clinical settings. CompuMed is headquartered in Los Angeles, CA. Visit CompuMed at www.compumedinc.com.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all passages containing words such as "will," "aims," "anticipates," "becoming," "believes," "continue," "estimates," "expects," "future," "intends," "plans," "predicts," "projects," "targets," or "upcoming." Forward-looking statements also include any other passages that are primarily relevant to expected future events or that can only be evaluated by events that will occur in the future. Forward-looking statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated or implied in the forward-looking statements. Factors that could cause actual results to vary from current expectations and forward-looking statements contained in this press release include, but are not limited to: the timing and volume of business activity from our clients and our ability to continue to provide products and services to such clients; the loss of, or reduction of business from, material clients; our liquidity and cash position; changes in technology; our ability to protect the Company's net operating losses and tax benefits; volatility and changes in our stock price, corporate or other market conditions; changes in government regulations or economic conditions; the impact of increased competition and pricing; capacity and supply chain constraints or difficulties; and other factors contained in the Company's filings posted on the OTC Markets website. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.

$CMPD CompuMed Inc. Announces Results of Shareholder VotingPress Release | 03/22/2022

LOS ANGELES, CA / ACCESSWIRE / March 22, 2022 / CompuMed, Inc. (OTC PINK:CMPD), a leader in providing diagnostic telemedicine, is pleased to announce publicly the vote results from the shareholder meeting held March 15th, 2022.

Results:

A total of 27,653,647 shares were voted at the meeting. This compares to total eligible voting shares of 42,291,070. Therefore a total of 65.4% of eligible shares were voted at the meeting.
Lee Keddie received 98.0% of all votes cast in favor of his candidacy for the board. Excluding the votes cast by VI Capital and the leadership team he received 96.4% of the votes cast in his favor.
Loren DenHerder received 98.0% of all votes cast in favor of his candidacy for the board. Excluding the votes cast by VI Capital and the leadership team he received 96.4% of the votes cast in his favor.
David Pointer received 96.4% of all votes cast in favor of his candidacy for the board. Excluding the votes cast by VI Capital and the leadership team he received 93.6% of the votes cast in his favor.
The proposal to effect a reverse stock split of 1:25 received 89.3% of all votes cast in favor of the proposal. Excluding the votes cast by VI Capital and the leadership team the proposal received 80.9% of votes cast in favor.
The Equity Incentive plan adoption received 86.1% of votes cast in favor of the plan. Excluding the votes cast by VI Capital and the leadership team the plan received 75.3% of votes cast in favor of adoption.

The Company is in the process of submitting the appropriate documents to FINRA for their review as well as working with our transfer agent ComputerShare to effect these actions as soon as possible.

About CompuMed, Inc.

CompuMed, Inc. (OTCPink:CMPD) Diagnostic Telemedicine services provide patients with the highest level of clinical care at reduced costs. Its telecardiology and teleradiology offerings provide real-time access to U.S. Board-Certified specialists through cloud-based technology and integrated medical devices to medical facilities anywhere in the world. The company has been in business over 26 years and services over 1,000 clinical settings. CompuMed is headquartered in Los Angeles, CA. Visit CompuMed at www.compumedinc.com.

Forward-Looking Statements

Statements contained in this report, such as statements about revenue, operations, and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company's plans, objectives, expectations and intentions are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission and OTC Pink operated by OTCMarkets. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.

CONTACT:

David W. Pointer
Chairman of the Board of CompuMed
(509) 226-0846

https://compumedinc.com/general-healthcare-industries/organprocurement/opo-testimonials/

From The CMPD News Release:

LOS ANGELES, Aug. 16, 2021 /PRNewswire/ -- CompuMed, Inc. (OTCPK: CMPD) ("CompuMed" or the "Company") is pleased to announce strong fiscal 2021 third quarter results.

FISCAL 2021 THIRD QUARTER HIGHLIGHTS:

Revenue in the quarter was $1.76 million,
an increase of 8.2% sequentially and 55.1% year-over-year.

Operating income during the quarter reached $250,000,
an increase of 56.8% sequentially and 150.2% year-over-year.

We enjoyed a great third quarter, and expect overall full year revenue growth to approximate 20%.

At quarter end CompuMed enjoyed a cash + accounts receivable position of $3.06 million,
7.2% higher than the second quarter and 21.2% higher than one

COMPUMED LAUNCHES A PROJECT TO EVALUATE THE USE OF AI THROUGH AIFORIA’S CLOUD-BASED SOFTWARE TO ENHANCE THE SPEED AND ACCURACY OF PATHOLOGY EVALUATION IN ORGAN TRANSPLANTATION.
CompuMed and its team of highly experienced physicians provide specialized diagnostic interpretations to their clients who need answers in high urgency situations. Organ Procurement Organizations (OPOs) which provide organs and tissue for transplant centers need critical information relating to for example pathology, cardiology, or radiology to improve donor management, decrease donor evaluation time prior to organ recovery, and to decrease the risk of organs being declined by transplant centers.

Many of the specialized physician interpretations needed for organ management and evaluation are best done by those that have expertise in that specific area. In addition, these services are often needed in a fast turnaround time, often at night, over the weekends and holidays. Many of the donor hospitals are often not very large centers, and even in larger hospitals, key resources tend to be mainly allocated to treating living patients.

“The OPO must often make do with late, and/or nontransplant-specific interpretations. Due to the large number of donor hospitals, over 50% of the donors come from a hospital that has less than two donors a year, this process involves a large number of pathologists, which by its very nature, results in inconsistencies,” explains Carie Kadric’, Vice President of Clinical Operations at CompuMed.

Part of the evaluation process by pathologists for transplantation may include a biopsy performed at the time of procurement. The transplant center must view the biopsy by viewing the actual slide, therefore it must be physically transported, meaning that the initial hospital must provide a “provisional acceptance”: they will accept the organ and once they receive delivery of the organ and slide, they can make a final decision. This does not allow multiple transplant centers to view the slide in a timely manner and adds hours of time to an already procured organ, increasing the probability of it degrading.

The ability to now digitize slides allows a smaller more specialized reading group of pathologists to perform slide interpretation creating more consistency by reducing the possibility of inter-observer bias. Digitized slides also allow multiple transplant centers to be able to view the slide remotely while reducing the trauma on the organ from multiple biopsies.

INCREASING THE SPEED AND PRECISION OF TRANSPLANT PATHOLOGY WITH AI
CompuMed wanted to investigate the benefits of using AI for the pathology process of their services, focusing on two specific functions. Firstly, in improving the “screening” of the biopsy slide prior to it reaching the remote pathologist. There are a number of thresholds that are required to be met for a biopsy to be an acceptable representation of the organ. For example, a minimum number of Glomeruli are required to be visible in a kidney biopsy, and the evaluation of the quality of the digital slide and the viable biopsy area are also critical.

“We felt that with the help of artificial intelligence we could greatly increase the confidence that what was being sent digitally to the pathologist would be acceptable and readable. This was especially important if the technician making the slide was on call as they may have already left by the time the pathologist indicated the slide or biopsy was unacceptable and they needed it to be redone,” describes Carie Kadric’.

The second function was to assist the pathologist in their evaluation to help improve efficiency, accuracy, and consistency. A renal slide from a kidney biopsy may take 10 to 15 minutes to read manually. Much of the time is spent covering the complete slide to count Glomeruli and determining if any are sclerosed, or damaged. With the assistance of AI, CompuMed anticipates they will be able to increase the speed and accuracy of this evaluation.

“We wanted to partner with a company that not only had a full AI platform that we could use ourselves, but we also wanted the flexibility of utilizing a platform that had a team that could do the AI development for us. In this way, we could utilize the AI team in the initial stages and any time we did not have the bandwidth,” explains Carie Kadric’. “ When we evaluated platforms, Aiforia came up at the top. But what really made the difference was the ease of working with their team. We feel the project has exceeded our expectations, not only with the resultant product, but also the value of the deliverable versus the cost.”

CompuMed is currently using Aiforia’s cloud-based platform for kidney transplant pathology and looking to expand to other organs such as the liver. The kidney project is using deep learning AI through Aiforia to count Glomeruli and to indicate sclerotic ones, giving pathologists confidence in their decision making by providing them with fast, high-precision data ava

https://www.aiforia.com/blog

CMPD Now Pink Current
https://www.otcmarkets.com/stock/CMPD/disclosure

Compumed Inc (CMPD)
0.3500 +0.0150 (+4.48%) 01/28/21 [OTC US]
BARCHART OPINION for Thu, Jan 28th, 2021Tutorial Alerts Watch Help
Overall Average:
100% BUY
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.

Barchart Opinion
INDICATOR
Opinion Strength & Direction
Composite Indicator
TrendSpotter
BUY
Short Term Indicators
20 Day Moving Average
BUY
20 - 50 Day MACD Oscillator
BUY
20 - 100 Day MACD Oscillator
BUY
20 - 200 Day MACD Oscillator
BUY
20 - Day Average Volume: 70,045 Average: 100% BUY
Medium Term Indicators
50 Day Moving Average
BUY
50 - 100 Day MACD Oscillator
BUY
50 - 150 Day MACD Oscillator
BUY
50 - 200 Day MACD Oscillator
BUY
50 - Day Average Volume: 52,268 Average: 100% BUY
Long Term Indicators
100 Day Moving Average
BUY
150 Day Moving Average
BUY
200 Day Moving Average
BUY
100 - 200 Day MACD Oscillator
BUY
100 - Day Average Volume: 41,077 Average: 100% BUY

NEWS OUT VERY POSITIVE.

CompuMed Announces Conversion of Series D Preferred Stock
LOS ANGELES, CA (January 8, 2021) -
CompuMed, Inc. (OTCPink:
CMPD), a leader in providing diagnosticm telemedicine, announced today that it has received notification from
VI Capital Fund, LP to convert the Series D Preferred shares held by VI Capital Fund, LP
into common shares according to the terms of the Series D Preferred Stock Agreement.
The Series D Preferred shares (4,167) held by VI Capital Fund, LP will therefore convert into 8,334,000 shares of CompuMed common stock.
After this conversion CompuMed will have only one class of equity interest; common stock.
We believe investors value a simple equity capital structure, and that removing any potential conflicts between equity classes enhances the value of the common shares of the Company.
We are delighted that VI Capital Fund, LP partners
have made this decision and believe that over time this more perfect alignment of interests will add value for all owners of CompuMed.
David Pointer, the representative for the Managing Partner for VI Capital Fund, LP (and also serving as CompuMedâ??s Chairman of the Board) commented that:
â??In a vote of VI Capital Fund partners they overwhelmingly supported the idea
of this conversion.
At VI Capital we recognize that any reasonable estimate of CompuMedâ??s value far exceeds the value floor determined by the Series D Preferred Stock agreement.
We do not therefore believe that any value exists for the
extra-ordinary rights those shares once had.
Accordingly, we are pleased to move forward with our equity interest in
CompuMed represented by common shares.
We are confident that removing any confusion regarding CompuMedâ??s
capital structure will be a positive event for all shareholders in the long-run.�
Less

What I"m FEELING yes feeling is pretyy interesting,There are a few interested parties in this company but don't believe they will give it away any thing under 5 bucks is not considered I hope imo.There new diagnostic is seeing positive results from costumers.there cash should be higher this quarter slowly but definitely there sales will return with a vengeance,there in the right field,for future telemedicine thats why the interest in compumed imo.They have potential,very good potential.next year will be great.We are building the foundations of a great company.

CMPD: Volume precedes price. Strong volume building. Up big soon.

CMPD @ .25: Massive Cleveland Clinic System partners for TeleMed?

Cleveland Clinic is rated the #2 Hospital system in the USA.

Expanding big in Florida & Midwest.

That news would be big.

Link:
https://go.clevelandclinicmycareonline.org/?gclid=Cj0KCQjwv7L6BRDxARIsAGj-34pi3bEeChhjZMyIihVwS4AWxMC5ZkqY3ke-SJuH_FP6dt9qqSZEzhAaArl0EALw_wcB

Additionally, we have been working hard to add a new diagnostic category
of services which we are currently testing with several customers.
I like to stress the wording they used ADD A NEW DIAGNOSTIC CATEGORY OF *****SERVICES**** SERVICES,MEANING MORE THEN ONE,MULTIPLE SERVICES,SHOULD BE INTERESTING.COULD BE WHAT THEY BEEN WAITING FOR,AND SEE CUSTOMERS REACTION.??

Lets hope your right,plus according to there last ER they're testing a new diagnostic tool that they have developed with several of there customers.Have absolutely no idea what it could be but it's something they been working on a few years to what I heard.

CMPD: Volume & price is up. Getting found by TeleMedine investors.

Down over 50% in two days.

like to see 3 bucks,will someone run this up there already,we know you want to.

WKEY @ $ 7.90: Major EV & Drone play. Hit $18 Wed. Robinhood play.

News:
https://www.wisekey.com/press/parrot-partners-with-wisekey-to-define-the-future-of-drone-security/

very quiet no action no nothing you woud think that the stock would trade higher due to the fact that telemedicine is exploding and this is a telemedicine comany,right.To damn quite no intetest at all nothing.Guess ER will not be so good crappy more like it I guess.Don"t know how they could screw this up with whats going on.Guess we will be very disappointed this week.Can't have one stock that actually rips goes crazy up after so many years of this crap.

Nobody is dumping chitt,volume is about 70thou which amounts to less then 18thou bucks which amounts to nothing. Some people selling probably because they need a few bucks maybe lost there jobs or something.If company is real,imo it is,yes they will have blowout earnings, absolutely.Guess we will find out soon enough.

CMPD: Fund dumping? They always know Earnings in advance.

Looking to buy one final batch before blowout 5/15 Earnings.

CMPD: Bought more ahead of great Earnings Report on 5/15

CMPD: Certainly got $1M Payroll Protect Grant. PR to follow.

TPTW got one.

TLSS got one.

Both are up big.

CMPD also got one, imo.

CMPD @.30: Blowout Earnings run underway...Earnings 5/15. On or before.

CMPD @ .29: Blowout Q2 Earnings getting closer. Move higher continues.

NEWS: AliveCor & OmRon Strategic Alliance. Huge increase in business for CMPD.


Great news.

LINK:
https://www.alivecor.com/press/press_release/alivecor-and-omron-announce-global-strategic-alliance-for-comprehensive-remote-cardiovascular-monitoring/

CMPD @ .28: Blowout Q2 (Jan-March) Earnings on 5/15...13 business days

$CMPD https://www.otcmarkets.com/stock/CMPD/news/CompuMed-Continuity-of-Telemedicine-Diagnostic-Services?id=257254

Any volume will send CMPD into .30s and higher.

CMPD: No sellers ahead of 5/15 blowout Earnings. Buyers will step up.

ain't no run yet,hopefully very very soon with at least 6 digit+ volume daily.And this penny BS hoping to see some real pps numbers like dollars.

Another strong day. Green on elevated volume. 5/15 Earnings run

Looking good...Breakout into .30s on tap. 5/15 Earnings on way.

CMPD @ .28: Last shares under .30 about to be gone. 5/15 Earnings run.

CMPD: Tele-Medicine. 16 Trading days till 5/15 blowout Earnings. Getting found.


Here is a list of medical sectors that CMPD provides Tele-medicine services.

The biggest foot print of any company.

LINK:
https://compumedinc.com/general-healthcare-industries/

Posted on CMPD website: Urgent Job Openings.

Job Openings:

URGENT NEED – PEDIATRIC CARDIOLOGISTS
CompuMed Inc., provides services in the organ donation and transplant field and has an urgent need for part-time Pediatric Cardiologists to perform echo interpretations and EKG overreads as part of a team assisting in Donor process. All work is done remotely using secure internet with CompuMed 24/7 support. Working with CompuMed can be scheduled into a traditional work schedule while generating a second source of income. Cardiologists must be licensed and Board-Certified and must have malpractice insurance of $1M per occurrence and $3M in the annual aggregate.

CMPD: Earnings run has begun. Blowout #s on 5/15. Great entry price now.

The 5/15 earnings will be sterling because the company is ALREADY profitable even without the sensational explosion of Tele-Medicine in recent months.

The 5/15 Earnings will set the stage for the new normal for CMPD...exceptional growth over next few years.

Mark my words.....CMPD is going to make huge gains and wind up on the Nasdaq within 18 months.

Do NOT miss CMPD at this price.

your right,it is a joke.This company is now in the hottest market there is there website very impressive,they haven't release any pr in 2 years they are as unknown as you could get,worst they are otc,but it doesn't mean that they're not involved or there business hasn't increase due to this pandemic crises I bet it increase significantly,,,but this mngt hasn't released anything yet ANYTHING but i bet there ER will make up for everything. Telemedicine will be the new norm now because of this crises telemedicine jumped 20 years forward in just under a month with estimates of a billion plus telemedicine diagnoses etc.No one can tell me that compumed is not involved one way or another. glta imo this is a no brainer.

CMPD: Last sub.30 cent shares being bought. 5/15 Earnings load up underway.

CMPD: Up 100% since 11/1/19 & getting found. Blowout 5/15 Earnings due.

CMPD dead stock walking. ZERO trades again and its a joke.

CMPD: Volume elevating ahead of sterling Q2 Earnings on 5/15/20.

Looking great.

19 Trading Days until great earnings.

TELE-MEDICINE: Great few weeks heading into CMPD 5/15/20 Q2 Earnings Report.


The last reported Quarter 1 was stellar,(Oct., Nov., Dec.) 2019.

Quarter 2, (Jan., Feb., March) 2020 was certainly much better.

Exciting to be in CompUMed now.

CMPD is at the center of the biggest tech transformation in medicine in history.

No technology has become so hot, so fast.

Tele-Medicine stocks are only just now getting found.

CMPD, heading into 5/15/20 will without doubt see big interest.

Load up and hang on.

CompUMed website:
https://compumedinc.com/

should be,earnings should be 2 million plus.I hoping 5 million plus but maybe zI am dreaming for now.But second imo definitely if we get real numbers this quarter.Need a good pr from company now.

Q2, 2020: Jan-Feb.-March: Earnings, May 15, will be very strong.

CMPD: Volume elevating last few days. Investors loading before 5/15

CMPD @ .295: Breakout to recent highs ahead of 5/15 Q1 Earnings on tap.

Do not miss this run.

CMPD a $5.00+ stock in time.....sooner that most think.

Buy CMPD now

Q1 Earnings. Jan.-Feb.-March on 5/15: Interest builds big into 5/15.

CMPD should get out in front of Q1 Earnings with a pre-announcement.

In addition, it is clear that CMPD is at least one of the Platforms.....and maybe the only Platform that KardiaMobile is using to read their hugely popular EKGs.

KardiaMobile:
https://store.alivecor.com/products/kardiamobile